XCUR (Exicure) Cyclically Adjusted Book per Share: $33.25 (As of Mar. 2026)


XCUR Exicure Inc XCUR
32 GF Score
Price $1.91
GF Value $0.54
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Exicure Cyclically Adjusted Book per Share?

Exicure XCUR -3.54% 32 Cyclically Adjusted Book per Share is $33.25 as of Mar. 2026. GuruFocus rates XCUR with a GF Score™ of 32/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Exicure's adjusted book value per share data for the fiscal year that ended in Dec. 2025 was $0.616. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $33.25 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-05), Exicure's current stock price is $ 1.91. Exicure's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec. 2025 was $33.25. Exicure's Cyclically Adjusted PB Ratio of today is 0.06.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of Exicure was 0.06. The lowest was 0.00. And the median was 0.00.


Exicure  (NAS:XCUR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Exicure's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.91/33.25
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of Exicure was 0.06. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Exicure Cyclically Adjusted Book per Share Related Terms


Exicure Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Exicure's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exicure Cyclically Adjusted Book per Share Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 33.25

Exicure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 33.25 0.00

XCUR vs TVRD, ANEB, HOWL: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Exicure's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exicure Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Exicure's Cyclically Adjusted PB Ratio falls into.


XCUR
32GF Score
Exicure Inc XCUR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exicure Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exicure's adjusted Book Value per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_Book=Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.616/324.0540*324.0540
=0.616

Current CPI (Dec. 2025) = 324.0540.

Exicure Annual Data

Book Value per Share CPI Adj_Book
201612 -152.783 241.432 -205.068
201712 75.951 246.524 99.837
201812 70.784 251.233 91.301
201912 140.674 256.974 177.395
202012 105.318 260.474 131.025
202112 15.492 278.802 18.006
202212 15.027 296.797 16.407
202312 1.752 306.746 1.851
202412 1.124 315.605 1.154
202512 0.616 324.054 0.616

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $33.25 mean?
Exicure (XCUR) has a Cyclically Adjusted Book per Share of $33.25 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Exicure and its competitors.
Is Exicure's Cyclically Adjusted Book per Share too high?
Exicure's current Cyclically Adjusted Book per Share is $33.25. Overall, Exicure has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exicure's Cyclically Adjusted Book per Share compare to TVRD and ANEB?
Exicure's Cyclically Adjusted Book per Share of $33.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Exicure and its competitors. Exicure's current Cyclically Adjusted Book per Share is $33.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exicure stock overvalued right now?
Based on GuruFocus' analysis, Exicure (XCUR) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $1.91 — trading 253.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is $33.25. Exicure's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Exicure (XCUR), the current Cyclically Adjusted Book per Share is $33.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exicure (XCUR) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of $1.91 is trading 253.7% above its estimated GF Value™ of $0.54. GuruFocus considers Exicure to be Significantly Overvalued.

Key valuation signals for XCUR:

  • Cyclically Adjusted Book per Share: $33.25
  • GF Value™: $0.54 vs. price of $1.91 (253.7% above fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the XCUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Exicure Business Description

Other Exchanges 2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
32GF Score

Get the complete analysis for XCUR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.91
Price
$0.54
GF Value